Klotho Protein Stabilization and Diagnostic Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of products or methods for providing exogenous human Klotho protein suitable for human use, particularly those that are compliant with FDA regulations, and for increasing endogenous Klotho protein levels in a safe and effective manner, as well as for monitoring Klotho protein levels or diagnosing Klotho protein deficiency in humans and animals.
Innovation Solution
Development of compositions and methods for stabilizing, monitoring, and increasing Klotho protein levels, including the production and administration of recombinant Klotho proteins, and the use of nutraceutical compositions to enhance endogenous production, along with diagnostic methods for Klotho protein deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant Klotho proteins are produced and administered to increase endogenous Klotho levels, then therapeutic benefits and age-related health condition treatment are improved, but compliance with FDA regulations and safety requirements becomes more complex and difficult to achieve
Solution Approach 1:
The patent uses nutraceutical compositions containing natural compounds (resveratrol, quercetin, curcumin, green tea catechins, and other polyphenols) as intermediaries to indirectly increase endogenous Klotho protein production rather than directly administering recombinant Klotho protein. This mediator approach allows the body's own cellular mechanisms to produce Klotho, thereby simplifying regulatory compliance while maintaining therapeutic efficacy for age-related health conditions.
2Measurement precision
If methods are developed to monitor and diagnose Klotho protein levels, then early detection of Klotho deficiency and personalized treatment are improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent implements feedback mechanisms by establishing baseline Klotho protein levels through monitoring methods (such as ELISA assays or other detection techniques) and periodically measuring Klotho levels in patients receiving nutraceutical treatment. This feedback loop enables clinicians to assess treatment efficacy, adjust dosages, and personalize therapy based on individual patient responses, thereby achieving precise measurement without requiring overly complex diagnostic systems.
3Ease of operation
If nutraceutical compositions are used to increase endogenous Klotho production, then safety and ease of administration are improved, but the time required to achieve therapeutic Klotho levels increases
Solution Approach 1:
The patent employs nutraceutical compositions containing multiple pre-selected compounds (resveratrol, quercetin, curcumin, green tea catechins, and other polyphenols) that have been preliminarily optimized for synergistic effects on Klotho production. These compositions are formulated in advance with specific dosages and combinations designed to maximize endogenous Klotho induction while maintaining safety, thereby reducing the time required to achieve therapeutic levels compared to single-compound approaches or non-optimized formulations.
Data Source
AI summary
Disclosed are products and methods for monitoring Klotho protein levels and for stabilizing Klotho protein in a mammalian blood sample, especially at room temperature or without freezing, for a period of time. Methods of detecting and quantifying Klotho protein levels, particularly endogenous and/or exogenous soluble alpha Klotho protein levels, methods of diagnosing Klotho protein deficiency, and methods of increasing Klotho protein levels or production, particularly endogenous and/or exogenous soluble alpha Klotho protein level(s), expression, or production, in a mammalian subject, and products useful in performing the same, including diagnostic kits and compositions for treating Klotho protein deficiency, are disclosed. Compositions are configured or formulated to augment natural soluble alpha Klotho protein production, attenuate Klotho protein damage or degradation, and/or supplement Klotho protein levels with exogenous, recombinant protein. Treatment methods and uses include administration of the compositions to human or non-human mammalian subjects.